Home – CDMO Solutions | Viral Vectors | Lentivirus
Over 30 years of lentiviral vector manufacturing
As a pioneer in lentiviral vector technology, OXB brings over three decades of proven experience to the development and manufacturing of lentiviral vectors for cell and gene therapies. Now a global CDMO, we support partners from early development through to commercialisation.
With over 340 GMP batches successfully manufactured, and 25 regulatory submissions supported, OXB offers deep regulatory, process, and analytical expertise to accelerate advanced therapy programmes from discovery to market.
OXB’s lentiviral vector track record
340+
GMP batches successfully released
25
Successful regulatory submissions
9
months
To GMP release
1.9E+
12 TU
At 200L scale
90%
Analytical assays performed in-house
8,000+
Patients’ doses
LentiVector™ platform
Taking novel therapies from discovery to commercialisation
OXB’s LentiVector™ platform offers a fully integrated and optimised suite of technologies and processes for the scalable production of high-quality lentiviral vectors. Designed to meet the complex demands of the cell and gene therapy market, the platform encompasses vector design, upstream and downstream processing, analytics, and fill/finish services, all aligned to deliver robust, reproducible GMP manufacturing.
The platform offers 3rd generation and 4th generation lentiviral vector systems, including proprietary innovations; 2KO genome™, SupA-LTR™, MaxPax™, and the TRiP System™, that together can enhance vector potency, productivity, quality, and safety.
With the LentiVector™ platform, clients benefit from high-yield, high-volume GMP manufacturing, scalable from early clinical to commercial supply, supported by deep regulatory expertise across global markets.
Explore the LentiVector™ platform
Our platform technologies:
Related resources
Vectors Without Borders: building a global viral vector CDMO
An inside look at OXB’s transformation into a global viral vector CDMO, including the expansion of its manufacturing network, faster delivery timelines and growing support for late-stage and commercial programmes. Based on an interview of OXB's Chief Business Officer, Sebastien Ribault and published in Manufacturing Today.
View details >
PPQ Readiness Guide
Preparing for PPQ? Explore six essential questions to help assess readiness, reduce risk and prepare your programme for commercial manufacturing.
View details >
In vivo CAR‑T – Reimagining Immune Engineering with Direct Cell Reprogramming
An overview of the opportunities and challenges of in vivo CAR-T therapy, including the technologies that could transform how next-generation cell therapies are delivered to patients. Published in The Medicine Maker.
View details >Late-Stage Capabilities One Pager
Learn how OXB supports the transition from late-stage development to commercial supply through proven expertise in process characterisation, PPQ, regulatory submissions and commercial-scale GMP manufacturing.
View details >
Isolating T-Cell Potent Lentiviral Vector Subpopulations through Rational Design of Nanofiber Anion-Exchange Adsorbents
This paper investigates lentiviral vector heterogeneity during anion-exchange chromatography and identifies a nanofiber-based purification approach that enhances recovery and separation of high-potency vectors.
View details >
Automation of Cell Based Assays: QC Implementation Strategies and Challenges
This presentation explores best practices for implementing automated platforms in QC environments, including strategies to address key challenges such as validation, data integrity, and change management. It also highlights the impact of automation on improving assay robustness and supporting regulatory compliance.
View Resource >Why choose OXB as your LV CDMO?
Taking novel therapies from discovery to commercialisation
Access innovative technology and unmatched expertise
With decades of leadership in lentiviral vector production, OXB gives clients access to some of the industry’s most experienced scientific minds. Our commitment to continuous innovation ensures clients benefit from the latest advancements in viral vector manufacturing to deliver best in class cell and gene therapies.
Receive comprehensive regulatory support through to commercialisation
OXB provides end-to-end regulatory support, guiding clients from preclinical development through to commercial launch. We have successfully supported multiple IND and MAA submissions, and maintain a Drug Master File (DMF) with the FDA, reinforcing our credibility as a trusted global CDMO partner.
Leverage local manufacturing with a global footprint
With harmonised lentiviral vector manufacturing processes across our UK, US, and European facilities, OXB enables efficient, scalable production from 50L to 1000L, close to your clinical or commercial markets. Our global footprint ensures flexibility, consistency, and speed—wherever you are.
Ways to work with us
There are multiple ways in which pharma, biotechs and start-ups work with us, depending on development phase, scale, and individual IP requirements.
Platform project
For clients that are pre-clinical or early-clinical that wish to reach GMP at an accelerated rate with a proven process.
Custom solution
For clients that are pre-clinical or early-clinical that require flexibility in the manufacture of their drug candidate.
Tech-transfer
For clients in phase I, II, or III that need to transfer their manufacture to a CDMO for scale and/or long-term manufacture.
Frequently asked questions
Yes, OXB has supported clients through every development phase from discovery, pre-clinical, clinical and commercial. We currently manufacture for 2 commercial programmes.
OXB has a suite of over 40 analytical methods, with 90% of these in-house. These include assays for measuring biological activity, identity, purity, quantity and safety.
OXB can tech transfer-in and out for products in any phase of development. We use a phase-appropriate 5 stage methodology designed to be adaptable, meeting the unique requirements of each client at various stages of development. Visit our resources hub to learn more about our tech transfer experience.
OXB has strong experience in supporting clients through commercialisation and currently manufactures for 2 commercial programmes. We have a proven track record in supporting global regulatory filings, including 30+ successful IND submissions and 2 BLA/MAA submissions.
Looking for something specific? – let's discuss a custom project
For pre-clinical clients that would like to co-develop a highly specific process, our custom project offering allows you to access OXB’s technology in combination with others to create a truly unique solution to meet your individual requirements.
